Current and novel approaches in the pharmacological treatment of hepatocellular carcinoma.

World J Gastroenterol · 2023 · PMC10198058 · PMID 37213397

Europe PMC DOI

hedged sentence

0.0752

closest p · 1.5× alpha

0.0752

boldest claim

The sentences

did not reach statistical significanceP = 0.0752so close (0.05 < p ≤ 0.1)

OS was improved from 14.7 mo for sorafenib to 16.4 mo with nivolumab but did not reach statistical significance ( P = 0.0752).

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.